Fibroblast Growth Factor Receptor 1 Activation in Mammary Tumor Cells Promotes Macrophage Recruitment in a CX3CL1-Dependent Manner

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Reed, Johanna R ^a   Stone, Matthew D ^a   Beadnell, Thomas C ^b   Ryu, Yungil ^b   Griffin, Timothy J ^a   Schwertfeger, Kathryn L ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; FRACTALKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST TUMOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; IN VITRO STUDY; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINE CX3CL1; EPITHELIAL CELLS; FEMALE; HUMANS; MACROPHAGES; MAMMARY GLANDS, ANIMAL; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, CHEMOKINE;

EID: 84866696098     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045877     Document Type: Article

References (60)

1. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, et al. (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121: 578-584.
2. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, et al. (1988) H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 263: 6579-6587.
3. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
4. Hu M, Polyak K, (2008) Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer 44: 2760-2765.
5. Reed JR, Leon RP, Hall MK, Schwertfeger KL, (2009) Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res 11: R21.
6. Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM, (2005) Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol 171: 663-673.
7. Bade LK, Goldberg JE, Dehut HA, Hall MK, Schwertfeger KL, (2011) Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor. J Cell Sci 124: 3106-3117.
8. Dickson C, Spencer-Dene B, Dillon C, Fantl V, (2000) Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res 2: 191-196.
9. Penault-Llorca F, Bertucci F, Adelaide J, Parc P, Coulier F, et al. (1995) Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 61: 170-176.
10. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, et al. (1997) Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 57: 4360-4367.
11. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, et al. (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70: 2085-2094.
12. Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, et al. (2011) FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 17: 5275-5286.
13. Presta M, Andres G, Leali D, Dell'Era P, Ronca R, (2009) Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. Eur Cytokine Netw 20: 39-50.
14. Andres G, Leali D, Mitola S, Coltrini D, Camozzi M, et al. (2009) A pro-inflammatory signature mediates FGF2-induced angiogenesis. J Cell Mol Med 13: 2083-2108.
15. Schwertfeger KL, Xian W, Kaplan AM, Burnett SH, Cohen DA, et al. (2006) A critical role for the inflammatory response in a mouse model of preneoplastic progression. Cancer Res 66: 5676-5685.
16. Bingle L, Brown NJ, Lewis CE, (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265.
17. Condeelis J, Pollard JW, (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266.
18. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67.
19. Pollard JW, (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
20. Joyce JA, Pollard JW, (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
21. Liu Y, Jiang P, Capkova K, Xue D, Ye L, et al. (2011) Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res 71: 6492-6502.
22. Muller A, Homey B, Soto H, Ge N, Catron D, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56.
23. Gil-Bernabe AM, Ferjancic S, Tlalka M, Zhao L, Allen PD, et al. (2012) Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood.
24. Ishida Y, Gao JL, Murphy PM, (2008) Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J Immunol 180: 569-579.
25. Koizumi K, Saitoh Y, Minami T, Takeno N, Tsuneyama K, et al. (2009) Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption. J Immunol 183: 7825-7831.
26. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A, (2004) CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 64: 4693-4698.
27. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, et al. (2006) Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17: 945-951.
28. Ferretti E, Bertolotto M, Deaglio S, Tripodo C, Ribatti D, et al. (2011) A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia 25: 1268-1277.
29. Marchesi F, Locatelli M, Solinas G, Erreni M, Allavena P, et al. (2010) Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J Neuroimmunol 224: 39-44.
30. Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Johrer K, et al. (2009) The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Lett 273: 127-139.
31. White GE, Greaves DR, (2009) Fractalkine: one chemokine, many functions. Blood 113: 767-768.
32. Lucas AD, Chadwick N, Warren BF, Jewell DP, Gordon S, et al. (2001) The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol 158: 855-866.
33. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, et al. (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640-644.
34. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, et al. (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102: 1186-1195.
35. Green SR, Han KH, Chen Y, Almazan F, Charo IF, et al. (2006) The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK. J Immunol 176: 7412-7420.
36. Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, et al. (2009) Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol 129: 1016-1025.
37. Xian W, Schwertfeger KL, Rosen JM, (2007) Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition. Mol Endocrinol 21: 987-1000.
38. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, et al. (2002) Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol 157: 703-714.
39. Geissmann F, Jung S, Littman DR, (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82.
40. Truman LA, Ford CA, Pasikowska M, Pound JD, Wilkinson SJ, et al. (2008) CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 112: 5026-5036.
41. Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, et al. (2003) Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 373: 547-558.
42. Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC, (2005) Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life 57: 441-447.
43. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, et al. (1998) NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 141: 1083-1093.
44. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J, (1995) Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 270: 14255-14258.
45. Bhavsar PK, Sukkar MB, Khorasani N, Lee KY, Chung KF, (2008) Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappaB. FASEB J 22: 1807-1816.
46. Graham K, Ge X, de Las Morenas A, Tripathi A, Rosenberg CL, (2010) Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res 17: 236-246.
47. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555.
48. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, et al. (2006) Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8: R23.
49. Lacroix M, Toillon RA, Leclercq G, (2004) Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 11: 497-522.
50. Park MH, Lee JS, Yoon JH (2012) High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol.
51. Valdivia-Silva JE, Franco-Barraza J, Silva AL, Pont GD, Soldevila G, et al. (2009) Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis. Cancer Lett 283: 176-185.
52. Lee SJ, Namkoong S, Kim YM, Kim CK, Lee H, et al. (2006) Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol 291: H2836-2846.
53. Yang XP, Mattagajasingh S, Su S, Chen G, Cai Z, et al. (2007) Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak Stat5 pathway. Circ Res 101: 1001-1008.
54. D'Haese JG, Demir IE, Friess H, Ceyhan GO, (2010) Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets 14: 207-219.
55. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, et al. (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530.
56. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH, (2010) The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 5: e8668.
57. Rappsilber J, Mann M, Ishihama Y, (2007) Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2: 1896-1906.
58. Bandhakavi S, Stone MD, Onsongo G, Van Riper SK, Griffin TJ, (2009) A dynamic range compression and three-dimensional peptide fractionation analysis platform expands proteome coverage and the diagnostic potential of whole saliva. J Proteome Res 8: 5590-5600.
59. Keller A, Nesvizhskii AI, Kolker E, Aebersold R, (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74: 5383-5392.
60. Yuen T, Zhang W, Ebersole BJ, Sealfon SC, (2002) Monitoring G-protein-coupled receptor signaling with DNA microarrays and real-time polymerase chain reaction. Methods Enzymol 345: 556-569.